Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on the Company's T-cell technology. It is engaged in the field of Precision Immunotherapy. The Company's product candidates include Tcelna and OPX-212. Tcelna and OPX-212 are not approved by the United States Food and Drug Administration (FDA) or other global regulatory agencies for marketing. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient's immune response profile to myelin. In addition to the Company's ongoing clinical development of Tcelna, the Company is also developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.